Pharmacy Medical News about Dasatinib;high-dose imatinib;chronic-phase chronic myeloid leukemia;resistant to imatinib

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily
Cancer, 06/23/09

Kantarjian H et al. - In a trial to assess the use of dasatinib and high-dose imatinib in chronic-phase chronic myeloid leukemia (CP-CML) resistant to imatinib, it was reported that after 2 yrs of follow-up, dasatinib demonstrated durable responses and improved response and progression-free survival (PFS) rates relative to high-dose imatinib.

Methods

A phase 2, open-label study was initiated of 150 pts with imatinib-resistant CP-CML who were randomized (2:1) to receive either dasatinib 70 mg twice daily (n=101) or high-dose imatinib 800 mg (400 mg twice daily; n=49).

Results

At a minimum follow-up of 2 yrs, dasatinib demonstrated higher rates of complete hematologic response (93% vs 82%), major cytogenetic response (MCyR) (53% vs 33%), and complete cytogenetic response (44% vs 18%).
At 18 mos, MCyR was maintained in 90% of pts on the dasatinib arm and in 74% of pts on the high-dose imatinib arm.
Major molecular response rates were more frequent with dasatinib than with high-dose imatinib (29% vs 12%).
Estimated PFS also favored dasatinib.

<< Previous
Minor Eye Problems in the Elderly

Next >>
Risk-Scoring Tool for respiratory syncytial virus prophylaxis in...